Engineers Gate Manager LP Aldeyra Therapeutics, Inc. Transaction History

Engineers Gate Manager LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$1.47 - $6.06 $84,004 - $346,304	57,146 New	57,146 $200,000
Q2 2023 Aug 14, 2023	SELL	$7.11 - $11.89 $5,865 - $9,809	-825 Reduced 5.88%	13,200 $110,000
Q1 2023 May 15, 2023	BUY	$5.77 - $9.93 $80,924 - $139,268	14,025 New	14,025 $139,000
Q1 2022 May 16, 2022	SELL	$3.25 - $5.17 $239,180 - $380,480	-73,594 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$3.5 - $9.63 $257,579 - $708,710	73,594 New	73,594 $294,000
Q1 2020 May 15, 2020	SELL	$1.62 - $6.4 $22,518 - $88,960	-13,900 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$4.73 - $7.98 $65,747 - $110,922	13,900 New	13,900 $81,000

116

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $298M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.